Along the way, researchers have assumed that the regulation of immune checkpoint pathways might have an impact on anti-tumor immunity, thereby leading to the successful administration of CTLA-4/PD-1-blocking antibodies to treat many types of cancers. This evidence concerns the gene PDCD1 and cancer.